Shanxi Meijin Energy (000723.SZ) announced that the company and the SiChuan Capital Markets Relief and Development Securities Investment Fund Partnership...
According to the news from Zhitong Finance APP, Shanxi Meijin Energy (000723.SZ) announced that the company, along with the SiChuan Capital Markets Relief and Development Securities Investment Fund Partnership (Limited Partnership), Jiaqiang (Shanghai) Consulting Co., Ltd., Zhejiang Orient Star Investment Management Co., Ltd., and Peking Zhonghan Orient Technology Development Co., Ltd., participated as a consortium in the public recruitment of investors for the reorganization of Changjiang Pharmaceutical Group (referred to as "Chang Pharmaceutical Group") and submitted an "Investment Proposal" to the temporary administrator of Chang Pharmaceutical Group.
The announcement shows that Chang Pharmaceutical Group is a listed company on the Shenzhen Stock Exchange, and together with its various subsidiaries, including Hubei Changjiang Xing Pharmaceutical Co., Ltd., has formed a main business primarily focused on pharmaceutical manufacturing, with an additional focus on the Photovoltaic Equipment business. The company's participation in this reorganization investment aims to enhance Chang Pharmaceutical Group's profitability and market competitiveness through deep collaboration, while also realizing complementary advantages between the company and Chang Pharmaceutical Group to leverage synergies.
Comment(0)
Reason For Report